Harmony Biosciences (HRMY) Expected to Announce Earnings on Tuesday

Harmony Biosciences (NASDAQ:HRMY) is anticipated to release its Q1 2025 earnings data before the market opens on Tuesday, April 29th. Analysts expect the company to announce earnings of $0.59 per share and revenue of $184.26 million for the quarter.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, February 25th. The company reported $0.85 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.11. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $201.30 million for the quarter, compared to the consensus estimate of $201.25 million. During the same quarter last year, the firm posted $0.45 EPS. The business’s revenue for the quarter was up 19.5% compared to the same quarter last year. On average, analysts expect Harmony Biosciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Harmony Biosciences Stock Up 0.1 %

Shares of NASDAQ HRMY opened at $28.50 on Tuesday. The stock has a fifty day moving average price of $32.74 and a 200 day moving average price of $34.41. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences has a 12-month low of $26.47 and a 12-month high of $41.61. The company has a market cap of $1.63 billion, a P/E ratio of 13.51, a P/E/G ratio of 0.47 and a beta of 0.80.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $50.00 price target on shares of Harmony Biosciences in a report on Tuesday, April 8th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Mizuho upped their price objective on shares of Harmony Biosciences from $42.00 to $44.00 and gave the company an “outperform” rating in a research report on Tuesday, March 18th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They set a “buy” rating and a $55.00 target price on the stock. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $53.33.

Insiders Place Their Bets

In other news, CFO Sandip Kapadia sold 1,775 shares of the stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $38.05, for a total transaction of $67,538.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Jeffrey Dierks sold 13,125 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $37.31, for a total value of $489,693.75. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,529 shares of company stock valued at $619,167. Company insiders own 23.60% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.